S. Barni, F. Romano, F. Petrelli, P. Tralongo
Vol.3 (2018), issue 1, pag.1-7

Received 20/11/2017
Accepted for pubblication 06/12/2017
Published Dec. 2017
Review by Single-blind
jQuery UI Dialog - Animation

In clinical practice the use of antiblastic treatments in the elderly population should carried out with caution and evaluated on the basis of individual variables, taking account of the risks, benefits and the prognosis of patients. The literature shows clearly the wide gap between what is well encoded in various scales of assessment of adverse events and what derives from patient reported outcomes. This issue should be implemented in clinical trials. Start clinical trials to better define the efficacy and the safety of these drugs in this subset of patients is a priority. In the geriatric patients, inact, the toxicity must be carefully evaluated, particularly in the presence of durable toxicity that can determine, in addition to the functional impairment. also the loss of indipendence. Particularly it is necessary to reassess the toxicity of grade 2, considering as serious toxicity for impact on health and quality of life. For elderly, clinical implications deriving from antiblastic toxicity are partially understood. Dose reduction, low compliance, hospitalization and therapy discontinuation affect clinical outcome expecially in presence of comorbidities. In this contest a low grade event is potentially a comorbidity that impairs health.